Content
06/09/2025
Redwood City, CA USA
Mosanna Therapeutics
completed $80 million Series A Round funding. Investors include
EQT Ventures (lead), Pivotal bioVenture Partners (lead), Forbion Capital Partners, Broadview Ventures, Norwest Venture Partners, Forty51 Ventures, Supermoon Capital, HTGF.
About
Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body's natural airway control during sleep, Mosanna's lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
